|Articles|May 4, 2021

High Vaccination Rates Are Key in Controlling the COVID-19 Pandemic

Author(s)Killian Meara

With a 75% vaccination rate, cases, hospitalizations and ICU administrations will plummet.

A recent study conducted by investigators and data scientists from the Mayo Clinic have demonstrated that high rates of vaccination are extremely important to reduce the number of cases and controlling the overall COVID-19 pandemic.

Results from the study were published in the journal Mayo Clinic Proceedings.

"It is difficult to untangle how much of this elevated rate of spread right now is due to new variants as opposed to changes in social behavior," the authors wrote. “Regardless of the reason, the absence of vaccinations in the current environment would have been likely to result in by far the largest surge to date."

For the study, the team of investigators developed a computer model that can forecast the impact that COVID-19 has on hospital usage. The predictive model was initially created to develop models of where and when COVID-19 hot spots would occur.

However, the investigators have now successfully employed the predictive model to accurately predict the timing and magnitude of COVID-19 cases and hospitalization surges. This information can aid hospital staff in preparing for any increase in patients.

Findings from the study showed that in Minnesota, if the state had achieved a vaccination rate of 75% by early April, cases, patients hospitalized and patients in the ICU with the virus would drop significantly by early July.

Additional findings demonstrated that if no vaccine was given in the state, over 800 patients would be in the ICU in the spring, more than double the current number.

“Comparing the range of predictions between scenarios offers compelling evidence for what many have assumed to be true. Namely, without vaccinations a large surge would be imminent,” the author wrote. “Conversely, vaccinations will suppress an otherwise inevitable surge of cases, but only if enough individuals take advantage of what modern science has provided.”


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.